A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Completed · Phase 3 · Has a placebo group

Conditions studied: Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

In brief

The purpose of this study is to evaluate the efficacy and safety of long-term treatment with lumacaftor in combination with ivacaftor in people 12 years and older with Cystic Fibrosis.

Key facts

Study ID

NCT01931839

Run by

Vertex Pharmaceuticals Incorporated

People needed

1164

Starts

2013-10-01

Expected to finish

2016-04-01

Last updated by the study team

2017-05-12

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent form (ICF), and where appropriate, signed assent form.
• Participants entering the Part A Treatment Cohort: Completed 24 weeks of study drug treatment in Study 103 or Study 104 and elect to enroll in Part A treatment cohort.
• Participants entering the Part B Treatment Cohort: Completed 56 days of study drug treatment in Cohort 4 of Study 102 and elect to enroll in Part B treatment cohort.
• Participants entering the Part A Observational Cohort: Completed 24 weeks of study drug treatment in Study 103 or Study 104, but do not elect to enroll in the Part A Treatment Cohort or do not qualify to enroll in Part A treatment cohort.
• Willing to remain on a stable CF medication regimen through the end of study (Part A and Part B Treatment Cohorts only).

You may not qualify if…

• Any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant (e.g., cirrhosis with portal hypertension).
• Pregnant and nursing females. Females of childbearing potential must have a negative pregnancy test at the Day 1 Visit.
• History of drug intolerance in the prior study that would pose an additional risk to the participant in the opinion of investigator or Vertex.
• History of poor compliance with study drug and/or procedures in the previous study as deemed by the investigator.
• Participation in an investigational drug trial (including studies investigating lumacaftor and/or ivacaftor, or studies requiring blood collections with or without administration of study drug)

Where it is running

• Study site — Anchorage, Alaska, United States
• Study site — Tucson, Arizona, United States
• Study site — Little Rock, Arkansas, United States
• Study site — La Jolla, California, United States
• Study site — Loma Linda, California, United States
• Study site — Longbeach, California, United States
• Study site — Los Angeles, California, United States
• Study site — Madera, California, United States
• Study site — Oakland, California, United States
• Study site — Palo Alto, California, United States
• Study site — Sacramento, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Denver, Colorado, United States
• Study site — Hartford, Connecticut, United States
• Study site — New Haven, Connecticut, United States
• Study site — Altamonte Springs, Florida, United States
• Study site — Hollywood, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Boise, Idaho, United States
• Study site — Chicago, Illinois, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.